TG THERAPEUTICS, INC. Basic Shares Outstanding (Weighted Average)
TG THERAPEUTICS, INC. (TGTX) reported Basic Shares Outstanding (Weighted Average) of 141.77 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 141.77M shares, a 3.39% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 144.44M shares, a 1.53% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 138.45M shares, a 4.68% decline year-over-year.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 145.42M shares, a 0.22% increase year-over-year.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 144.32M shares, a 0.69% decline from fiscal 2024.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 145.32M shares, a 2.37% increase from fiscal 2023.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 141.96M shares, a 4.83% increase from fiscal 2022.
- TG THERAPEUTICS, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 135.41M shares, a 2.41% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 141.77M shares 10-Q · filed 2026-08-05 | 143.10M shares 10-Q · filed 2026-08-05 | 141.55M shares derived: average of 3 quarters · filed 2026-08-05 | 142.52M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 144.44M shares 10-Q · filed 2026-05-06 | 141.44M shares derived: average of 2 quarters · filed 2026-05-06 | 142.77M shares derived: average of 3 quarters · filed 2026-05-06 | 143.76M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 138.45M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 141.93M shares derived: average of 2 quarters · filed 2026-02-27 | 143.53M shares derived: average of 3 quarters · filed 2026-08-05 | 144.32M shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 145.42M shares 10-Q · filed 2025-11-05 | 146.08M shares derived: average of 2 quarters · filed 2026-08-05 | 146.27M shares 10-Q · filed 2025-11-05 | 146.02M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 146.74M shares 10-Q · filed 2026-08-05 | 146.71M shares 10-Q · filed 2026-08-05 | 146.22M shares derived: average of 3 quarters · filed 2026-08-05 | 145.94M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 146.68M shares 10-Q · filed 2026-05-06 | 145.96M shares derived: average of 2 quarters · filed 2026-05-06 | 145.67M shares derived: average of 3 quarters · filed 2026-05-06 | 145.44M shares derived: average of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | 145.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 145.17M shares derived: average of 2 quarters · filed 2026-02-27 | 145.02M shares derived: average of 3 quarters · filed 2026-02-27 | 145.32M shares 10-K · filed 2026-02-27 |
| 2024-09-30 | 145.10M shares 10-Q · filed 2025-11-05 | 144.91M shares derived: average of 2 quarters · filed 2025-11-05 | 145.34M shares 10-Q · filed 2025-11-05 | 144.79M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | 144.73M shares 10-Q · filed 2025-08-08 | 145.46M shares 10-Q · filed 2025-08-08 | 144.68M shares derived: average of 3 quarters · filed 2026-02-27 | 144.23M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | 146.21M shares 10-Q · filed 2025-05-09 | 144.66M shares derived: average of 2 quarters · filed 2026-02-27 | 144.06M shares derived: average of 3 quarters · filed 2026-02-27 | 143.42M shares derived: average of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | 143.11M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 142.99M shares derived: average of 2 quarters · filed 2026-02-27 | 142.49M shares derived: average of 3 quarters · filed 2026-02-27 | 141.96M shares 10-K · filed 2026-02-27 |
| 2023-09-30 | 142.87M shares 10-Q · filed 2024-11-07 | 142.19M shares derived: average of 2 quarters · filed 2024-11-07 | 141.57M shares 10-Q · filed 2024-11-07 | 140.45M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | 141.50M shares 10-Q · filed 2024-08-09 | 140.91M shares 10-Q · filed 2024-08-09 | 139.65M shares derived: average of 3 quarters · filed 2025-03-03 | 138.57M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | 140.31M shares 10-Q · filed 2024-05-06 | 138.72M shares derived: average of 2 quarters · filed 2025-03-03 | 137.59M shares derived: average of 3 quarters · filed 2025-03-03 | 136.89M shares derived: average of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | 137.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 136.23M shares derived: average of 2 quarters · filed 2025-03-03 | 135.74M shares derived: average of 3 quarters · filed 2025-03-03 | 135.41M shares 10-K · filed 2025-03-03 |
| 2022-09-30 | 135.33M shares 10-Q · filed 2023-11-06 | 135.05M shares derived: average of 2 quarters · filed 2023-11-06 | 134.84M shares 10-Q · filed 2023-11-06 | 134.27M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 134.78M shares 10-Q · filed 2023-08-04 | 134.59M shares 10-Q · filed 2023-08-04 | 133.91M shares derived: average of 3 quarters · filed 2024-02-29 | 133.52M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 134.40M shares 10-Q · filed 2023-05-08 | 133.48M shares derived: average of 2 quarters · filed 2024-02-29 | 133.10M shares derived: average of 3 quarters · filed 2024-02-29 | 132.85M shares derived: average of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 132.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 132.46M shares derived: average of 2 quarters · filed 2024-02-29 | 132.33M shares derived: average of 3 quarters · filed 2024-02-29 | 132.22M shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 132.35M shares 10-Q · filed 2022-11-09 | 132.21M shares derived: average of 2 quarters · filed 2022-11-09 | 132.11M shares 10-Q · filed 2022-11-09 | |
| 2021-06-30 | 132.07M shares 10-Q · filed 2022-08-09 | 131.99M shares 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | 131.90M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 115.33M shares 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |